Study samples
| Samples . | Disease activity . | Elevated MIP-1α . |
|---|---|---|
| Stage I MM | Inactive | 0/2 |
| Stage III MM | Inactive | 3/16 |
| Stage III MM | Active | 8/13* |
| Others | — | 3/14 |
| Normal controls | — | 0/7 |
| Cell lines | — | 4/5 |
| Samples . | Disease activity . | Elevated MIP-1α . |
|---|---|---|
| Stage I MM | Inactive | 0/2 |
| Stage III MM | Inactive | 3/16 |
| Stage III MM | Active | 8/13* |
| Others | — | 3/14 |
| Normal controls | — | 0/7 |
| Cell lines | — | 4/5 |
MIP-1α levels were considered significantly elevated if they were 2 SD above the upper limit of MIP-1α detected in bone marrow plasma from 7 normal individuals; that is, 42.49 + 2 (15.9). MIP-1α levels were measured by ELISA in 2 patients with MM stage I, 16 patients with MM stage III with inactive disease, 13 patients with MM stage III with active disease, 14 patients with non-MM neoplasias, 7 normal controls, and 5 LCLs. The proportion of patients with elevated levels of MIP-1α > 75 pg/mL was significantly higher among patients with MM stage III active disease when compared to all other groups studied (8 of 13 versus 0 of 2, 3 of 16, 3 of 14, 0 of 7, respectively;P < .05). Levels of MIP-1α were highly elevated (>1500 pg/mL) in 4 of 5 LCLs examined.
P < .05.